Opinion|Videos|December 9, 2024

Safety Profiles of Bispecific Antibodies for RRMM

Panelists discuss how bispecific antibody therapies in relapsed/refractory multiple myeloma commonly present with cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and increased infection risks, while talquetamab specifically exhibits distinctive adverse events including nail changes, skin reactions, and oral toxicities.

Video content above is prompted by the following

  • Provide a brief overview of typical toxicities seen with bispecific therapies for RRMM, namely CRS/ICANS and infection risks.
  • Describe the unique toxicities seen with talquetamab, namely nail-related, skin-related, and oral-related toxicities.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Latest CME